Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Harun Muğlu"'
Publikováno v:
İstanbul Medical Journal, Vol 21, Iss 1, Pp 17-19 (2020)
Waldenström’s macroglobulinaemia is a disease in the B lymphoproliferative diseases group with immunoglobin M monoclonality and may present with different clinical manifestations. A 52-year-old male patient presented with complaints of weight loss
Externí odkaz:
https://doaj.org/article/74fab9843f2c48aab2b579656f48f806
Autor:
Sabin Göktaş Aydın, Yasin Kutlu, Harun Muğlu, Özgür Açıkgöz, Ahmet Aydın, Ahmet Bilici, Ömer Ölmez, Dilek Ünal, Ebru Karcı, Özcan Yıldız
Objective: Androgen pathway inhibitors have a significant impact on the treatment of prostate cancer. The treatment approach is controversial in patients who develop oligo-pro-gression under anti-androgen therapy. This study aimed to in-vestigate the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::623dc948818f448cebe07abe4fc18153
https://hdl.handle.net/20.500.12511/11088
https://hdl.handle.net/20.500.12511/11088
Publikováno v:
İstanbul Medical Journal, Vol 21, Iss 1, Pp 17-19 (2020)
Waldenström’s macroglobulinaemia is a disease in the B lymphoproliferative diseases group with immunoglobin M monoclonality and may present with different clinical manifestations. A 52-year-old male patient presented with complaints of weight loss
Autor:
Deniz Can Guven, Musa Baris Aykan, Harun Muglu, Ertugrul Bayram, Kaan Helvaci, Bengü Dursun, Melisa Celayir, Elvin Chelebiyev, Erdinc Nayir, Mustafa Erman, Ahmet Sezer, Yuksel Urun, Umut Demirci, Ozlem Er, Umut Disel, Ahmet Bilici, Cagatay Arslan, Nuri Karadurmus, Saadettin Kilickap
Publikováno v:
Cancer Medicine, Vol 13, Iss 1, Pp n/a-n/a (2024)
Abstract Introduction The advances in immune checkpoint inhibitors (ICIs) were relatively slow in rare tumors. Therefore, we conducted a multi‐center study evaluating the efficacy of ICI monotherapy and the combination of ICIs with chemotherapy (CT
Externí odkaz:
https://doaj.org/article/0f697c742e7245d3a185d956a2ca5f1a
Autor:
Harun Muglu, Erdem Sunger, Celalettin Herek, Ozcan Sonmez, Fatih Pektas, Erdal Gundogan, Hakan Sari, Ahmet Engin Atay, Numan Gorgulu
Publikováno v:
Bagcilar Medical Bulletin, Vol 3, Iss 1, Pp 11-13 (2018)
Allopurinol is a well-known drug to treat hyperuricemia in patients with chronic kidney disease, gout, or tumor lysis syndrome. The most common side effects are nausea, vomiting, elevated liver enzyme, pancreatitis, and skin rashes. Drug reaction wit
Externí odkaz:
https://doaj.org/article/6ae129a65c2a426ca1d312d1bc537cda